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Introduction: Soluble mesothelin (SM) and megakaryocyte poten-
tiating factor (MPF) are serum biomarkers of mesothelioma. This
study aims to examine the longitudinal behavior of SM and MPF in
controls to gain insight in the optimal use of these biomarkers in
screening.
Methods: Asbestos-exposed individuals, with no malignant disease at
inclusion, were surveilled for 2 years with annual measurements of SM
and MPF. Fixed thresholds were set at 2.10 nmol/L for SM and 13.10
ng/ml for MPF. Longitudinal biomarker analysis, using a random
intercept model, estimated the association with age and glomerular
filtration rate (GFR), and the intraclass correlation. The latter represents
the proportion of total biomarker variance accounted for by the be-
tween-individual variance.
Results: A total of 215 participants were included, of whom 179 and
137 provided a second sample and third sample, respectively. Two
participants with normal SM and MPF levels presented afterward
with mesothelioma and lung cancer, respectively. Participants with
elevated biomarker levels were typically older and had a lower GFR.
During follow-up, biomarker levels significantly increased. Longi-
tudinal analysis indicated that this was in part due to aging, while
changes in GFR had a less pronounced effect on serial biomarker
measurements. SM and MPF had a high intraclass correlation of
0.81 and 0.78, respectively, which implies that a single biomarker
measurement and fixed threshold are suboptimal in screening.
Conclusions: The longitudinal behavior of SM and MPF in controls
indicates that a biomarker-based screening approach can benefit
from the incorporation of serial measurements and individual-spe-
cific screening rules, adjusted for age and GFR. Large-scale valida-
tion remains nevertheless mandatory to elucidate whether such an
approach can improve the early detection of mesothelioma.
Key Words: Soluble mesothelin, Megakaryocyte potentiating fac-
tor, Mesothelioma, Screening, Asbestos.
(J Thorac Oncol. 2011;6: 889–895)
Malignant pleural mesothelioma is a rare asbestos-relatedmalignancy with a fatal outcome.1 Because of its nonspe-
cific presenting symptoms, patients often suffer a substantial
diagnostic delay, resulting in a more advanced disease at diag-
nosis. An adequate screening program and subsequent earlier
detection might improve patient outcome.2 Current guidelines
on mesothelioma management do, however, not advocate the
use of screening and recommend that the efficacy of any screen-
ing tool should be further evaluated in high-risk populations.1
Although serum biomarkers such as CA125 and cytokeratins
were found to be ineffective in mesothelioma screening,2 the
advent of more accurate serum biomarkers of mesothelioma,
such as soluble mesothelin (SM) and megakaryocyte potentiat-
ing factor (MPF)3,4 could change prospects. We have recently
shown that these two biomarkers, which both originate from the
mesothelin precursor protein,5 are highly correlated and have an
equivalent diagnostic performance.6 While MPF is not yet eval-
uated in mesothelioma screening, the use of a single SM mea-
surement and a fixed threshold reveals disappointing results in
retrospective screening studies.7–9 Nevertheless, it has been
demonstrated, especially in ovarian cancer screening, that a
single biomarker measurement and fixed screening threshold are
suboptimal in the presence of a high between-individual bio-
marker variance, and screening can be improved by incorporat-
ing serial biomarker measurements and individual-specific
screening rules.10,11
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To determine whether SM and MPF are suitable for
such screening approach, it is important that the normal
(longitudinal) behavior of these biomarkers is first ascer-
tained.10 Serial SM and MPF measurements have, however,
not been prospectively assessed in controls. In addition,
although we and others have recently shown that both age and
glomerular filtration rate (GFR) affect single SM and MPF
measurements12–14 (Hollevoet et al., unpublished data), it is
unclear to what extent longitudinal changes of these clinical
covariates affect serial biomarker measurements and should
be accounted for.
The aim of this prospective study is to examine the
normal longitudinal behavior of SM and MPF, including
biomarker variance and the effect of age and GFR, to gain
insight in the optimal use of these biomarkers in screening.
We, therefore, surveilled a cohort of asbestos-exposed indi-
viduals, with no malignant disease at inclusion, for 2 years
with annual biomarker measurements.
PATIENTS AND METHODS
Participants
Between November 2007 and July 2010, individuals
with professional asbestos exposure, and no malignant dis-
ease, were consecutively enrolled and surveilled for 2 years at
either the Belgian Occupational Diseases Fund, the four
participating departments of Respiratory Medicine, or two
companies with a history of asbestos processing. At inclu-
sion, a blood sample was taken, and participants were appro-
priately examined to assess the presence of a benign asbestos-
related condition and exclude malignant disease. After
approximately 1 and 2 years, participants were invited, by
written notice and telephone conversation, for a follow-up
visit, at which blood sampling was repeated and a brief health
inquiry was conducted. Because of privacy regulation, no
motivation was requested when participants declined the
invitation. If the participant reported no complaints, no addi-
tional examinations were performed. Serum samples were
coded and stored in aliquots at 80°C. This study was
approved by the ethics committee of all participating hospi-
tals, and all participants gave written informed consent before
inclusion. Biomarker test results were handled in a double-
blinded fashion and not communicated to participants and
responsible physicians.
Characteristics
Age and GFR (ml/min/1.73 m2) were recorded at in-
clusion and follow-up. GFR was estimated with the Chronic
Kidney Disease Epidemiology Collaboration equation,15
based on serum creatinine levels. A GFR above 90 ml/min/
1.73 m2 is considered normal, whereas a lower GFR repre-
sents a decrease in renal function.15 The quantity of past
asbestos exposure was estimated in fiber years. Participants
were thereto interviewed by trained staff of the Occupational
Diseases Fund using a standardized questionnaire.16 One fiber
year equals the exposure of 106 fibers/m3 during 1 year.
Biomarker Assays
Serum SM (nmol/L) and MPF levels (ng/ml) were
measured using the Mesomark (Cis bio International, Gif sur
Yvette, France) and Human MPF ELISA kit (Medical &
Biological Laboratories, Nagano, Japan), respectively, ac-
cording to the manufacturer’s instructions.4,17 Analyses were
performed in a single laboratory, blinded to the coded sample
data, shortly after sample collection. SM and MPF levels
were considered elevated when exceeding 2.10 nmol/L and
13.10 ng/ml, respectively. These fixed thresholds were ob-
tained by differentiating the baseline biomarker levels of the
asbestos-exposed participants and 106 patients with mesothe-
lioma at a specificity of 95% (Hollevoet et al., unpublished
data).
Statistical Analysis
Variables are reported as median with 25th to 75th per-
centiles. Biomarker levels were compared between independent
and dependent groups using the nonparametric Mann-Whitney
U and paired Wilcoxon test, respectively. Spearman’s rank
analysis determined the correlation between the different vari-
ables. Longitudinal analysis of SM and MPF was done using
residual maximum likelihood estimation under a random inter-
cept model with a residual autoregressive covariance structure,
with age and GFR as covariates (allowing for both within- and
between-individual age and GFR effects). This allowed to ade-
quately account for dropouts and differences in sampling time
among participants. As we focused on the biomarker behavior in
controls, participants who developed a malignancy during fol-
low-up were excluded from this analysis. Biomarker levels were
transformed on the common logarithmic scale to improve model
fit. To enable interpretation on the original scale, the reported
model’s coefficients were exponentiated (i.e., raised to the 10th
power). The variances of the random intercept (2b) and the
residual error term (2) represent the between- and within-
individual variance of the logarithmic biomarker levels, respec-
tively. The 95% prediction intervals at a given age and GFR
stretch out up to a factor exp(1.96*) from the corresponding
geometric mean, where 2  2b  
2
. Intraclass correlation,
the proportion of total variance in biomarker levels accounted
for by the between-individual variance, was estimated as
2b/(
2
b  
2
). A high intraclass correlation is consequently
suggestive of a substantial between-individual biomarker vari-
ance, relative to the total variance in the data. This implies that
a substantial improvement in screening can be obtained when
using information from serial biomarker measurements, as com-
pared to using a single measurement and fixed threshold.10,11 All
hypothesis tests were performed two sided at the 5% level of
significance. Statistical analysis was done with statistical soft-
ware SPSS (version 17.0, Chicago, IL) and SAS (version 9.2,
SAS Institute, Cary, NC).
RESULTS
Participants
A total of 215 individuals were included, of whom 126
(59%) had a benign asbestos-related condition, including
pleural plaques (n  71), diffuse pleural thickening (n 39),
and other lesions, mainly asbestosis (n  16). Eighty-nine
(41%) had no radiologically obvious asbestos-related lesions.
A second sample and third blood sample were obtained in
179 (84%) and 137 (64%) individuals (Table 1), respectively,
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with a median follow-up time after inclusion of 12.2 months
(11.8–13.0) and 24.2 months (22.0–24.6), respectively.
Biomarker Levels
At inclusion, SM and MPF levels positively correlated
with age (rSM  0.44, rMPF  0.31, p  0.001) and inversely
with GFR (rSM  0.32, rMPF  0.24, p  0.001). When
using the fixed SM and MPF thresholds, 20 and 21 partici-
pants, respectively, had an elevated level, either at baseline or
follow-up, of whom 14 had both biomarker levels above
threshold (Table S1, Supplementary data). In all participants
with an elevated SM and MPF level and follow-up samples
available, respectively, 10 and nine, biomarker levels re-
mained above the threshold. At each sampling point, those
with an elevated biomarker level were significantly older and
had a lower GFR than those with normal biomarker levels
(p  0.001, Table S1, Supplementary data).
Severe Events
During the course of the study, seven severe events,
including four deaths, were reported, all in individuals with a
benign asbestos-related condition at inclusion (Table 2).
Three participants presented a malignancy during follow-up,
including one malignant pleural mesothelioma. After his
initial inclusion in May 2008, the second blood sample was
only obtained approximately 2 years later, because the patient
did not respond to the first follow-up invitation. At this
follow-up, the patient reported pleurisy and a persistent
cough. A pleural effusion was found, and thoracoscopic
biopsy further established the diagnosis of a stage III epithe-
lioid mesothelioma. Interestingly, this patient had normal and
stable biomarker levels. Elevated biomarker levels were only
observed in the patient with a prostate cancer and the indi-
vidual who had a paralyzing stroke. Noteworthy, these two
were among the elder of the seven participants and had the
lowest GFR. Similarly, the individuals with the lowest bio-
marker levels were also the youngest and had the highest
GFR (Table 2).
Asbestos Exposure
Fiber years were estimated in 204 participants (95%).
In patients with a benign asbestos-related condition, fiber
years did not differ with the type of condition (p  0.66) but
were significantly higher (40.0 fiber years, 22.0–116.8) than
in the healthy asbestos-exposed (15.8 fiber years, 6.1–40.6,
p 0.001). At baseline, fiber years positively correlated with
SM (p  0.05, r  0.15) and age (p  0.001, r  0.37),
inversely with GFR (p 0.01, r0.21), and not with MPF
(p  0.13, r  0.11). A multiple (forward) linear regression
analysis with fiber years as response variable revealed an
independent association with age (p  0.05), whereas no
association with SM (p  0.73), MPF (p  0.98), or GFR
(p  0.44) was found.
Longitudinal Behavior of the Biomarker Levels
The biomarker levels were strongly correlated across
the three sampling points (Figure 1). Nevertheless, in the 137
participants of whom all three samples were available, SM
and MPF levels significantly increased (p  0.001) during
follow-up (Figure 2). Of interest, the longitudinal biomarker
analysis revealed a significant effect of aging on the serial
measurements (pSM  0.001, pMPF  0.001) (Table 3). For
example, a 1-year increase in age increased geometric mean
SM and MPF levels with 18% (95% CI  15–20%) and 14%
(95% CI  12–17%), respectively. In contrast, the effect of
GFR was less pronounced and only significant in SM (pSM 
0.001, pMPF 0.39) (Table 3). For example, a decrease of 10
TABLE 1. Baseline and Follow-Up Characteristics
Baseline First Follow-Up
Second
Follow-Up
Number
(female)
215 (18) 179 (16) 137 (14)
Healthy/ARD
(%)
41/59 49/51 58/42
SM (nmol/L) 0.96 (0.74–1.37) 1.18 (0.96–1.54) 1.21 (0.98–1.66)
MPF (ng/ml) 6.64 (5.20–8.88) 7.60 (6.16–10.00) 8.40 (6.48–10.57)
Age (yr) 55.7 (51.9–66.1) 55.8 (52.4–64.8) 55.7 (53.0–60.7)
GFR (ml/min/
1.73 m2)
79.5 (66.2–90.8) 78.5 (66.7–88.5) 82.2 (69.8–91.4)
Variables are reported as median with 25th–75th percentile.
ARD, benign asbestos-related disease; SM, soluble mesothelin; MPF, megakaryo-
cyte potentiating factor; GFR, glomerular filtration rate.
TABLE 2. Severe Events and Characteristics
Condition at Inclusion Event
Baseline Available Follow-Up
SM
(nmol/L)
MPF
(ng/ml)
Age
(yr)
GFR
(ml/min/1.73 m2)
SM
(nmol/L)
MPF
(ng/ml)
Age
(yr)
GFR
(ml/min/1.73 m2)
Plaques Epithelioid pleural
mesothelioma
1.76 10.56 75.9 47.7 1.61 10.00 77.8 48.1
Asbestosis and plaques Fatal lung cancer 0.64 5.04 64.0 85.3 — — — —
DPT Prostate cancer 3.51 26.48 79.7 33.1 — — — —
DPT and plaques Paralyzing stroke 2.98 17.28 78.9 19.4 — — — —
DPT and plaques Fatal cardiac failure 0.85 5.32 66.9 88.9 — — — —
Asbestosis Fatal cardiac failure 1.52 9.28 74.0 53.3 — — — —
Plaques Deceaseda 1.76 8.12 84.6 61.7 2.09 11.52 85.6 61.3
a Unknown cause.
DPT, diffuse pleural thickening; SM, soluble mesothelin; MPF, megakaryocyte potentiating factor; GFR, glomerular filtration rate.
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ml/min/1.73 m2 resulted in an increase of 4% (95%CI 1–6%)
in geometric mean SM levels, respectively. Furthermore, aging
accounted for 22% and 15% of the within-individual SM and
MPF variance, respectively, whereas changes in GFR explained
only 1% for both biomarkers. Combining between- and within-
individual biomarker variance resulted in a high intraclass cor-
relation of 0.81 for SM and 0.78 for MPF.
DISCUSSION
To examine the longitudinal behavior of SM and MPF
in controls, a cohort of asbestos-exposed individuals, with no
malignant disease at inclusion, was surveilled for 2 years with
annual biomarker measurements. Past asbestos exposure of
these participants, estimated in fiber years, was weakly cor-
related with SM levels. In contrast, regression analysis found
FIGURE 1. Spearman rank correlation plots between baseline and first follow-up levels of (A) soluble mesothelin (SM) and
(C) megakaryocyte potentiating factor (MPF); and between baseline and second follow-up levels of (B) SM and (D) MPF.
FIGURE 2. Box plot of (A) soluble me-
sothelin (SM) and (B) megakaryocyte po-
tentiating factor (MPF) levels of the 137
participants in whom a sample at base-
line, follow-up visit 1 (FU 1), and fol-
low-up visit 2 (FU 2) was available. Bio-
marker levels significantly increased over
time, ***p  0.001.
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no independent association, and the observed correlation was
likely due to the interrelationship between fiber years, age,
GFR, and SM. Biomarker levels were consequently not
useful to estimate an individual’s past asbestos exposure. For
SM, this was in agreement with previous findings,8,18–20
except for one report that suggested an association with
asbestos exposure, based on a difference in SM levels be-
tween healthy and asbestos-exposed individuals.21 These
groups, however, differed substantially in age, and it is
possible that the reported effect was age related, rather than
asbestos related. For MPF, the relationship with past asbestos
exposure had not been reported previously.
In contrast to MPF, the use of a single SM measure-
ment and a fixed threshold in screening for mesothelioma has
been evaluated. In a first retrospective study by Robinson et
al.,3 three of seven asbestos-exposed individuals with ele-
vated SM levels were later diagnosed with mesothelioma. In
addition, two of eight patients with mesothelioma had ele-
vated SM levels before diagnosis.3 Large retrospective stud-
ies did, however, not confirm these promising findings. Using
a threshold of 2.3 nmol/L, Roe et al.7 found that only 1 of 77
prediagnostic samples (1%) had an elevated SM level. Cre-
aney et al.8 demonstrated, using a 2.5 nmol/L threshold, that
17 of 106 patients with mesothelioma (16%) had an elevated
SM level before diagnosis. Most recently, Gube et al.9 found
that 2 of 20 patients with mesothelioma (10%) had a predi-
agnostic SM level above a threshold of 1.5 nmol/L. In a first
prospective study, 538 individuals were surveilled for 1 year,
whereas SM levels were only measured at baseline.22 From
the 15 (3%) who had a level above 2.5 nmol/L, one had
chronic renal failure but no malignancy, another had an
early-stage lung cancer, and a third had a suspected cardiac
tumor. In the 12 other individuals, no malignancies were
observed. Two participants with normal SM levels died
during the course of the study due to lung and pancreatic
cancer, respectively.22
Altogether, these disappointing results seem not in
favor of incorporating SM in screening for mesothelioma.
SM deserves, however, some credit, as the design of these
studies often hampered an appropriate evaluation of its use.
First, typical of retrospective studies, a too long period (1
year) between analyzed “prediagnostic” samples and the
actual presentation of mesothelioma could underestimate the
efficacy of SM.7,9 Second, in the prospective study, the size of
study population and duration of the follow-up were not in
proportion with the low incidence and long latency period of
mesothelioma.22 This was also the case in our series. The
finding that a participant with normal biomarker levels pre-
sented a mesothelioma is consequently of limited relevance.
Third, the high intraclass correlation of SM and MPF in our
series clearly indicated that the use of a single biomarker
measurement and fixed screening threshold is suboptimal.10,11
Fourth, none of these studies took age or GFR into account.
The association of these covariates with SM and MPF12–14
(Hollevoet et al. Clinical covariates and prognostic value
of soluble mesothelin and megakaryocyte potentiating fac-
tor: implications for clinical use, submitted for publica-
tion) is, however, especially relevant in screening, as it can
easily lead to false positives. In our series, individuals with
elevated biomarker levels were, for example, typically
older and had a low GFR. This was also illustrated in an
elderly participant with a severely decreased GFR; his
biomarker levels were highly elevated, but he presented
with a prostate cancer, a malignancy which is not associ-
ated with mesothelin overexpression.23
The high intraclass correlation of SM and MPF indi-
cated that screening can benefit from incorporating serial
biomarker measurements. Our report is the first to prospec-
tively examine the longitudinal behavior of such SM and
MPF measurements in controls. Although the number of
follow-up samples decreased after initial inclusion, the re-
trieved study population still allowed for significant and
critical observations. Biomarker levels were strongly corre-
lated across the sampling points but surprisingly increased
during follow-up. Analysis of the within-individual bio-
marker variance revealed that a substantial proportion of this
increase was due to aging. The impact of GFR was limited,
most likely because GFR changes little in 2 years. It is
probable that larger differences in GFR, occurring over a
longer period of time, can have a more pronounced effect on
serial biomarker measurements. Assay variability and other
within-individual changes accounted for the remaining with-
in-individual biomarker variance.
Our findings allowed to speculate on the optimal design
of a biomarker-based screening approach for mesothelioma.
Although the use of a single baseline biomarker measurement
alone is unlikely to be effective, it could act as a first triage
and risk-stratification step.11 An alternative for a fixed thresh-
old could be the implementation of age- and GFR-adjusted
biomarker reference values. After this initial triaging, further
follow-up would then be guided by changes in serial bio-
marker measurements, accounted for aging and changes in
GFR. Importantly, such biomarker-based screening approach
will only be effective if serial SM and MPF measurements
increase relatively more in patients who will develop meso-
thelioma compared with those who remain disease free. Two
recent retrospective studies have examined the behavior of
serial prediagnostic SM measurements. Creaney et al.8 re-
ported a serial biomarker-based screening algorithm, which
detected 33 of the 88 (38%) patients with mesothelioma, up
to 2 years before diagnosis. This was substantially higher
than the 16% detected when applying a single measurement
at a fixed threshold and illustrates the potential of a serial
biomarker-based approach.8 Nevertheless, when extrapolat-
ing this algorithm to our series, 26% (35/137) would have
TABLE 3. Random Intercept Model Estimates of the Within-
Individual Effect of Age and GFR on Biomarker Levels
Biomarker Parameter Coefficient SE 95% CI p
Log(SM) Age 0.071 0.005 0.062 to 0.081 0.0001
GFR 0.067 0.005 0.077 to0.057 0.0001
Log(MPF) Age 0.058 0.005 0.048 to 0.067 0.0001
GFR 0.001 0.005 0.002 to 0.001 0.390
SM, soluble mesothelin; MPF, megakaryocyte potentiating factor; GFR, glomerular
filtration rate; SE, standard error; CI, confidence interval.
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tested positive at the third follow-up visit. As indicated by the
authors, their algorithm is possibly skewed by the retrospec-
tive sample analysis, in which assay variability was mini-
mized.8 This can explain the high fraction of “positives” in
our series and illustrates the influence of a prospective col-
lection on biomarker variance. Most recently, Gube et al.9
evaluated serial measurements of a panel of serum biomark-
ers, including SM, in screening for mesothelioma but did not
find a clear trend in 20 prediagnostic samples. In this study,
the time considered between the prediagnostic samples and
presentation of the tumor was up to 11 years, likely under-
estimating the efficacy of serial measurements. While these
two reports illustrate the challenges in developing and vali-
dating an efficient algorithm, neither of them accounted for
age or GFR. Further research is consequently mandatory to
ascertain whether a serial biomarker-based screening ap-
proach is suitable for the early detection of mesothelioma.
This requires the analysis of a large enough amount of
retrospective samples, collected in a serial manner in cohorts
in which a sufficient number of individuals developed meso-
thelioma, followed by prospective validation.24
Besides the accuracy of a screening tool, other issues
are equally important in early detection. For a rare malig-
nancy such as mesothelioma, a positive predictive value of
10% can be considered sufficient for a screening approach.25
Nevertheless, when considering, for example, a biomarker
with a sensitivity of 60% and a specificity of 95%, a positive
predictive value of 10% requires a prevalence of at least 1 of
100, emphasizing that screening is only worthwhile in a
population with a very high probability of disease. Further-
more, for screening to be justifiable, treatment of early-stage
disease should improve outcome, and it is still uncertain
whether this is the case for mesothelioma.26 In addition,
although a detectable preclinical phase of the disease should
ideally be present, a tumor must reach a certain size before it
can be detected by imaging modalities such as computed
tomography and positron emission tomography, and very
early changes are difficult to observe and nonspecific among
other asbestos-related lesions.26 Progress in these fields is
consequently mandatory before large-scale screening efforts
can make a true difference.
In conclusion, this prospective study reveals important
insights on the longitudinal behavior of SM and MPF, which
can aid future screening approaches. The impact of age and
GFR, both on single and serial biomarker measurements,
together with the substantial biomarker variance, indicates
that a single biomarker measurement and fixed threshold are
suboptimal in screening. A biomarker-based screening ap-
proach can consequently benefit from incorporating serial
measurements and individual-specific screening rules. Large-
scale validation remains nevertheless mandatory to elucidate
whether such an approach can improve the early detection of
mesothelioma.
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